COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Clinical Trial to Compare Apatinib Plus Irinotecan Versus Single Irinotecan as Second-line Treatment in AGC or EGJA

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03030937
Recruitment Status : Unknown
Verified January 2017 by Fujian Cancer Hospital.
Recruitment status was:  Not yet recruiting
First Posted : January 25, 2017
Last Update Posted : January 25, 2017
Information provided by (Responsible Party):
Fujian Cancer Hospital

No Study Results Posted on for this Study
Recruitment Status : Unknown
Estimated Primary Completion Date : July 31, 2018
Estimated Study Completion Date : December 30, 2018